Sitagliptin Improves Plasma Apolipoprotein Profile in Type 2 Diabetes: A Randomized Clinical Trial of Sitagliptin Effect on Lipid and Glucose Metabolism (SLIM) Study.

[1]  M. Elisaf,et al.  Apolipoprotein CIII and diabetes. Is there a link? , 2019, Diabetes/metabolism research and reviews.

[2]  P. Kovanen,et al.  Triglyceride-Rich Lipoproteins as a Source of Proinflammatory Lipids in the Arterial Wall. , 2019, Current medicinal chemistry.

[3]  E. Boerwinkle,et al.  Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. , 2018, Journal of the American College of Cardiology.

[4]  S. Kihara,et al.  Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial) , 2017, Journal of atherosclerosis and thrombosis.

[5]  Chang Ho Ahn,et al.  Effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on lipid metabolism and endotoxemia after a high‐fat meal in patients with type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[6]  R. Holman,et al.  Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS , 2016, Diabetes Care.

[7]  Yifen Liu,et al.  Diabetes Dyslipidemia , 2016, Diabetes Therapy.

[8]  A. Tenenbaum,et al.  Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two–Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry , 2016, Circulation. Cardiovascular quality and outcomes.

[9]  H. Sugihara,et al.  Repetitive Glucose Spikes Accelerate Atherosclerotic Lesion Formation in C57BL/6 Mice , 2015, PloS one.

[10]  G. Lewis,et al.  Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism , 2015, Diabetes.

[11]  S. Rajagopalan,et al.  Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors , 2015, Clinical lipidology.

[12]  A. Droit,et al.  Effect of sitagliptin therapy on triglyceride‐rich lipoprotein kinetics in patients with type 2 diabetes , 2014, Diabetes, obesity & metabolism.

[13]  K. Yamagishi,et al.  Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). , 2014, Atherosclerosis.

[14]  S. Weisnagel,et al.  Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. , 2014, Metabolism: clinical and experimental.

[15]  A. Sharrett,et al.  Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage , 2014, Circulation.

[16]  G. Lewis,et al.  Sitagliptin, a DPP-4 Inhibitor, Acutely Inhibits Intestinal Lipoprotein Particle Secretion in Healthy Humans , 2014, Diabetes.

[17]  Yoshiya Tanaka,et al.  Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus , 2013, Journal of Diabetes Investigation.

[18]  H. Morita,et al.  Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report , 2013, Cardiovascular Diabetology.

[19]  S. Yamashita,et al.  Correlation of fasting serum apolipoprotein B‐48 with coronary artery disease prevalence , 2012, European journal of clinical investigation.

[20]  F. Sacks,et al.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  S. Yamashita,et al.  Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[22]  D. Figeys,et al.  Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins , 2011, The Journal of Biological Chemistry.

[23]  S. Weisnagel,et al.  Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[24]  S. Yamashita,et al.  Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus. , 2008, Diabetes research and clinical practice.

[25]  P. Schnohr,et al.  [Non-fasting triglycerides and risk of for myocardial infarction and death among women and men]. , 2007, Ugeskrift for laeger.

[26]  M. Taskinen,et al.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes , 2006, Diabetologia.

[27]  D. Drucker,et al.  Glucagon and glucagon-like peptide receptors as drug targets. , 2006, Current pharmaceutical design.

[28]  J. Holst,et al.  Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans , 2006, Diabetologia.

[29]  Peter Libby,et al.  The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.

[30]  K. Reynolds,et al.  Relationship between HbA1c level and peripheral arterial disease. , 2005, Diabetes care.

[31]  Ralph B D'Agostino,et al.  Trends in cardiovascular complications of diabetes. , 2004, JAMA.

[32]  Henrik Vestergaard,et al.  The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. , 2004, Archives of internal medicine.

[33]  Alfonso T. Perez,et al.  Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes , 2004, Diabetes & vascular disease research.

[34]  G. Watts,et al.  Identification of Lipoproteins of Intestinal Origin in Human Atherosclerotic Plaque , 2003, Clinical chemistry and laboratory medicine.

[35]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[36]  R. Eckel,et al.  Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. , 2003, Diabetes care.

[37]  K. Jablonski,et al.  Effects of isolated post-challenge hyperglycemia on mortality in American Indians: the Strong Heart Study. , 2003, Annals of epidemiology.

[38]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[39]  S. Nilsson,et al.  Functional Analyses of Human Apolipoprotein CII by Site-directed Mutagenesis , 2002, The Journal of Biological Chemistry.

[40]  G. Reaven,et al.  Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. , 2001, Journal of the American College of Cardiology.

[41]  S. Saydah,et al.  Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. , 2001, Diabetes care.

[42]  M. Fujishima,et al.  Diabetes and Cardiovascular Disease in a Prospective Population Survey in Japan: The Hisayama Study , 1996, Diabetes.

[43]  J. Breslow,et al.  Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. , 1994, The Journal of clinical investigation.

[44]  S. Oikawa,et al.  Appearance of multidisperse low density lipoprotein and altered lipoprotein composition in non-insulin-dependent diabetes with type IIa hyperlipoproteinemia. , 1989, Metabolism: clinical and experimental.

[45]  R. Schwartz,et al.  Increase of adipose tissue lipoprotein lipase activity with weight loss. , 1981, The Journal of clinical investigation.

[46]  H. Soran,et al.  Diabetic dyslipidaemia. , 2016, Current opinion in lipidology.

[47]  S. Ito,et al.  Establishment of monoclonal antibody against human Apo B‐48 and measurement of Apo B‐48 in serum by ELISA method , 1998, Journal of clinical laboratory analysis.